secwatch.observer — SEC 8-K summary
======================================

Issuer:     COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK:        0001267565
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001628280-26-011990
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Collegium Q4 net rev $205.4M (+13% YoY); FY 2025 rev $780.6M (+24%); reaffirms 2026 guidance
--------------------------------------------------------------------------------

- Q4 GAAP diluted EPS $0.46 vs $0.36 YoY; adjusted diluted EPS $2.04 vs $1.77.
- Jornay PM Q4 net revenue $45.9M (+57%); full-year $148.9M (+48%).
- Pain portfolio FY 2025 net revenue $631.7M (+6%); Belbuca $221.7M (+5%).
- Full-year adjusted EBITDA $460.5M (+15%); cash & marketable securities $386.7M.
- Closed $980M credit facility in Dec; repurchased $25M shares in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1267565/000162828026011990/0001628280-26-011990-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1267565/000162828026011990/coll-20260226.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-011990

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer